Publications
246
Citations
6,722
Est. group size
~19
Recurring co-author estimate
Active years
42
Publishing since 1985
Mark P. Rubinstein's research focuses on immunotherapy for cancer, particularly how immune signaling molecules like interleukin-15 (IL-15) and adoptively transferred T cells (immune cells taken from a patient, modified, and reinfused to fight tumors) can be used to destroy tumors. His work spans basic immunology of CD8+ T cells and B cells, engineering of cellular and antibody-based therapies, and translational/clinical studies such as biomarker tracking in pancreatic cancer. This suggests a research group bridging laboratory immunology with clinical cancer treatment development.
Publication output was relatively steady (6-15 papers/year) from 2017-2022, spiked sharply in 2023 (93 items, likely including multiple linked data/supplementary files from a single study), then returned to a steady rate of around 11-12 per year in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Use of serial ctDNA dynamics to predict clinical outcomes in metastatic and locally advanced PDAC: A systematic review.
Journal of Clinical Oncology · 2026
- Cytisinicline for Smoking Cessation
JAMA Internal Medicine · 2025
- Constructing the cure: engineering the next wave of antibody and cellular immune therapies
Journal for ImmunoTherapy of Cancer · 2025
- IL-15: from discovery to FDA approval
Journal of Hematology & Oncology · 2025
- B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity
UNC Libraries · 2025
- Molecular landscape and site of metastasis in PDAC.
Journal of Clinical Oncology · 2024
- Supplemental Figures from Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8<sup>+</sup> T Cells
2023
- Data from Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8<sup>+</sup> T Cells
2023
- Supplemental Figures from Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8<sup>+</sup> T Cells
2023
- Data from Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8<sup>+</sup> T Cells
2023
- Data from Interleukin-15/Interleukin-15Rα Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8<sup>+</sup> T Cells
2023
- Supplementary Figure 1 from Interleukin-15/Interleukin-15Rα Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8<sup>+</sup> T Cells
2023
- Supplementary Figure 2 from Interleukin-15/Interleukin-15Rα Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8<sup>+</sup> T Cells
2023
- Supplementary Figure 4 from Interleukin-15/Interleukin-15Rα Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8<sup>+</sup> T Cells
2023
- Supplementary Figure 4 from Interleukin-15/Interleukin-15Rα Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8<sup>+</sup> T Cells
2023
- Journal of Clinical Oncology×8
- Regular and Young Investigator Award Abstracts×7
- Cancer Immunology Research×5
- Cancer Research×5
- Journal for ImmunoTherapy of Cancer×5
- John V. Napoleon
Medicine · Purdue University West Lafayette
- Chunyu Xu
Medicine · Purdue University West Lafayette
- Bihui Cao
Medicine · Indiana University
- Lynn O’Donnell
Medicine · The Ohio State University
- Jianhua Yu
Immunology and Microbiology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile